HomeCompareDNB vs ABBV

DNB vs ABBV: Dividend Comparison 2026

DNB yields 1.64% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.3K in total portfolio value
10 years
DNB
DNB
● Live price
1.64%
Share price
$9.15
Annual div
$0.15
5Y div CAGR
-10.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$55.20
Full DNB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DNB vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNB
Annual income on $10K today (after 15% tax)
$139.34/yr
After 10yr DRIP, annual income (after tax)
$46.92/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,009.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNB + ABBV for your $10,000?

DNB: 50%ABBV: 50%
100% ABBV50/50100% DNB
Portfolio after 10yr
$61.7K
Annual income
$12,413.48/yr
Blended yield
20.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DNB
Analyst Ratings
8
Buy
7
Hold
Consensus: Buy
Price Target
$19.17
+109.5% upside vs current
Range: $12.00 — $24.00
Altman Z
0.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNB buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNBABBV
Forward yield1.64%3.06%
Annual dividend / share$0.15$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-10.9%40.6%
Portfolio after 10y$21.1K$102.3K
Annual income after 10y$55.20$24,771.77
Total dividends collected$949.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$19.17$256.15

Year-by-year: DNB vs ABBV ($10,000, DRIP)

YearDNB PortfolioDNB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,846$146.07$11,550$430.00$704.00ABBV
2$11,737$131.92$13,472$627.96$1.7KABBV
3$12,678$118.88$15,906$926.08$3.2KABBV
4$13,672$106.92$19,071$1,382.55$5.4KABBV
5$14,725$96.02$23,302$2,095.81$8.6KABBV
6$15,842$86.11$29,150$3,237.93$13.3KABBV
7$17,028$77.15$37,536$5,121.41$20.5KABBV
8$18,289$69.05$50,079$8,338.38$31.8KABBV
9$19,631$61.76$69,753$14,065.80$50.1KABBV
10$21,060$55.20$102,337$24,771.77$81.3KABBV

DNB vs ABBV: Complete Analysis 2026

DNBStock

Dun & Bradstreet Holdings, Inc. provides business decisioning data and analytics in North America and internationally. It offers finance and risk solutions, including D&B Finance Analytics, an online application that offers clients real time access to its information, comprehensive monitoring, and portfolio analysis; D&B Direct, an application programming interface (API) that delivers risk and financial data directly into enterprise applications for real-time credit decision making; D&B Small Business, a suite of powerful tools that allows SMBs to monitor and build their business credit file; D&B Enterprise Risk Assessment Manager, a solution for managing and automating credit decisioning and reporting; and InfoTorg, an online SaaS application. The company also provides risk and compliance solutions, such as D&B Supplier Risk Manager that provides insights to help certify, monitor, analyze, and mitigate risk across the supply chain; D&B Onboard to provide comprehensive insights into businesses to facilitate KYC/AML compliance, as well as to minimize financial, legal, and reputational risk exposure; and D&B Beneficial Ownership that offers risk intelligence on ultimate beneficial ownership. It offers sales and marketing solutions, including D&B Connect, a self-service data management platform; D&B Optimizer, an integrated data management solution; D&B Rev.Up ABX, an open and agnostic platform that aligns marketing and sales teams to deliver an optimal and coordinated buying; D&B Hoovers, a sales intelligence solution; D&B Audience Targeting, which helps clients to reach the right audiences with the right messages; D&B Visitor Intelligence that turns web visitors into leads; and D&B Direct, an API-enabled data management solution that delivers valuable customer insights into CRMs, marketing automation, and other marketing applications for on-demand business intelligence. The company was founded in 1841 and is headquartered in Jacksonville, Florida.

Full DNB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DNB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNB vs SCHDDNB vs JEPIDNB vs ODNB vs KODNB vs MAINDNB vs JNJDNB vs MRKDNB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.